Document is current
Any future updates will be listed below
-
Authors
O’Donnell, Kyle L. https://orcid.org/0000-0002-7183-1966
Anhalt, Hanna https://orcid.org/0000-0002-0799-3039
Saturday, Greg https://orcid.org/0000-0002-0803-6177
Warner, Nikole L. https://orcid.org/0000-0002-2307-5529
Hinkley, Troy https://orcid.org/0000-0003-4833-0255
Stone, E. Taylor
Hatzakis, Kiara
Khandhar, Amit P.
Banadyga, Logan https://orcid.org/0000-0001-8390-2648
Erasmus, Jesse H. https://orcid.org/0000-0003-1612-2697
Marzi, Andrea https://orcid.org/0000-0003-0186-9587
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI001254)
HDT Bio
- License Information
-
More Information
Article History
Received: 4 August 2024
Accepted: 25 April 2025
First Online: 6 May 2025
Competing interests
: N.L.W., E.T.S., K.H., T.H., A.P.K. and J.H.E. receive a salary and have equity interests in HDT Bio. J.H.E. is an inventor on US patent application no. 62/993,307 “Compositions and methods for delivery of RNA” pertaining to the LION formulation for vaccine development. There are no restrictions on the publication of research data. The remaining authors declare no competing interests.
